Natural history and clinical consequences of hepatitis B virus infection

International Journal of Medical Sciences

Volumn 2, Issue 1, 2005, Pages 36-40

  Pan, Calvin Q ^a,c   Zhang, Jin X ^b  

^a ELMHURST HOSPITAL CENTER   (United States)

^b MOUNT SINAI HOSPITAL   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Cirrhosis; Hepatitis B; Hepatocellular carcinoma; Natural history

Indexed keywords

HEPATITIS B(E) ANTIGEN;

ACUTE HEPATITIS; CHRONIC HEPATITIS; CONVALESCENCE; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; DISEASE TRANSMISSION; DNA SEQUENCE; FOLLOW UP; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HEALTH CARE DELIVERY; HEPATITIS B; HEPATITIS B VIRUS; HETEROZYGOTE; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; IMMUNE STATUS; IMMUNOLOGICAL TOLERANCE; INCUBATION TIME; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; MORBIDITY; MORTALITY; ONSET AGE; PATIENT CARE; PRIMARY INFECTION; PROGNOSIS; REVIEW; T LYMPHOCYTE; VACCINATION; VIREMIA; VIRUS CELL INTERACTION; VIRUS MUTANT; VIRUS REPLICATION;

EID: 21744449452     PISSN: 14491907     EISSN: 14491907     Source Type: Journal    
DOI: 10.7150/ijms.2.36     Document Type: Review

References (32)

1. Kidd-Ljunggren K, Miyakawa Y, et al. Genetic variability in hepatitis B viruses. J Gen Virol 2002;83:1267-1280.
2. Arauz-Ruiz P, Norder H, Robertson BH, et al. Genotype H: A new meridian genotype of hepatitis B virus revealed in Central America. J Gen Virol 2002;83:2059-2073.
3. Kao JH, Chen PJ, Lai MY, Chen DS. Genotypes and clinical phenotypes of hepatitis B virus in patients with chronic hepatitis B virus infection. J Clin Microbiol 2002;40:1207-1209.
4. McMahon BJ, Holck P, Bulkow L, et al. Serologic and clinical outcomes of 1536 Alaska natives chronically infected with hepatitis B virus. Ann Internal Med 2001;135:759-768.
5. Sumi H, Yokosuka O, Seki N, et al. Influence of hepatitis B virus genotypes on the progression of chronic hepatitis B liver disease. Hepatology 2003;37:19-26.
6. Chu CJ, Lok ASF. Clinical significance of hepatitis B virus genotypes. Hepatology 2002;35:1274-1276.
7. Chu CJ, Keeffe EB, Han SY, et al. Prevalence of HBV precore/core promoter variants in the United States. Hepatology 2003;38:619-628.
8. Perrillo RP. Acute flares in chronic hepatitis B: The Natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 2001;120:1009-1022.
9. Fattovich G. Natural history of hepatitis B. Journal of Hepatology 2003, 39: S50-S58.
10. McMahon BJ, Alberts SR, Wainwright RB et al. Hepatitis B-related sequelae. Prospective study in 1400 hepatitis B surface antigen-positive Alaska Native carriers. Arch Intern Med 1990;150:1051-4.
11. Merican I, Guan R, Amarapuka D et al. Chronic hepatitis B virus infection in Asian countries. Journal of Gastroenterology and Hepatology 2000; 15: 1356-1361.
12. Hoofnagle JH. Serologic markers of hepatitis B virus infection. Annu Rev Med 1981;32:1-11.
13. Ribeiro RM, Lo A, Perelson AS, et al. Dynamics of hepatitis B virus infection. Microbes Infect 2002;4:829-35.
14. Lok ASF, Lai CL, Wu PC, et al. Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection. Gastroenterology 1987;92:1839-43.
15. Bortolotti F, Cadrobbi P, Crivellaro C, et al. Long-term outcome of chronic type B hepatitis in patients who acquire hepatitis B virus infection in childhood. Gastroenterology 1990;99:805-10.
16. Funk ML, Rosenberg DM, Lok ASF. World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants. J Viral Hepat 2002;9:52-61.
17. Keefe Emmet, Dieterich Douglas, Steve-Huy B, et al. A treatment Algorithm for the management of Chronic Hepatitis B Virus Infection in the United States. Clinical Gastroenterology and Hepatology 2004;2:87-106.
18. Papatheodoridis GV, Manesis E, Hadziyannis SJ, et al. The long-term outcome of interferon-Alpha treated and untreated patients with HbeAg-negative chronic hepatitis B. J Hepatol 2001;34:306-13.
19. Lok ASF, McMahon BJ. Chronic hepatitis B. Hepatology 2001;34:1225-41.
20. Hsu YS, Chien RN, Yeh CT, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002;35:1522-7
21. De Franchis R, Meuccie G, Vecchi M, et al. The Natural history of asymptomatic hepatitis B surface antigen carriers. Ann Intern Med 1993;118:191-4.
22. Bellentani S, Dal Molin G, Miglioli L, et al. Natural history of HBV infection: a 9 years follow-up of the Dionysos cohort. J Hepatol 2002;36(Suppl. 1):228.
23. Rossi G, Pelizzari A, Motta M, et al. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HBsAg carriers with lymphoid malignancies treated with chemotherapy. Br J Hematol 2001; 115:58-62
24. Chan TM, Fang GX, Tang CSO, et al. Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients. Hepatology 2002; 36:1245-52.
25. de Jongh FE, Janssen HL, de Man RA, et al. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of liver. Gastroenterology 1992;103:1630-1635.
26. Fattovich G, Giustina G, Schalm SW, et al. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. Hepatology 1995;21:77-82.
27. Kao JH, Chen PJ, Lai MY, et al. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 2000;118:554-9.
28. Fattovich G, Pantalena M, Zagni I et al. Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort of 297 patients. Am J Gastroenterology 2002;97:2886-95.
29. Beasley RP. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 1988;61:1942-56.
30. Benvegnue L, Fattovich G, Noventa F et al. Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. Cancer 1994;74:2442-8.
31. Tsai JF, Jeng JE, Ho MS, Chang WY et al. Effect of hepatitis C and B virus infection on risk of hepatocellular carcinoma: a prospective study. Br J Cancer 1997;76:968-74.
32. Yang HI, Lu SN, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002;347:168-174.